Exelixis
Develops and commercializes cancer medicines around cabozantinib and a broader oncology pipeline.
$54.00
After-hours close−0.42 (−0.77%)
At close$54.42(−1.52%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $0.89 | — | — |
| Aug 2026 | $0.85 | $0.91 | +6.7% |
| May 2026 | $0.75 | $0.87 | +16.0% |
| Feb 2026 | $0.77 | $0.94 | +22.1% |
| Nov 2025 | $0.69 | $0.78 | +13.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| Apr 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Oct 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Sep 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | $0.89 | — | — | $650.3M | — | — |
| Aug 5, 2026 | $0.85 | $0.91 | +6.7% | $636.4M | $628.7M | −1.2% |
| May 5, 2026 | $0.75 | $0.87 | +16.0% | $607.5M | $610.8M | +0.5% |
| Feb 10, 2026 | $0.77 | $0.94 | +22.1% | $596.5M | $598.7M | +0.4% |
| Nov 4, 2025 | $0.69 | $0.78 | +13.9% | $590.2M | $597.8M | +1.3% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Jul 28, 2025 | ||||||
| May 13, 2025 | ||||||
| Feb 11, 2025 | ||||||
| Oct 29, 2024 | ||||||
| Aug 6, 2024 | ||||||
| Apr 30, 2024 | ||||||
| Feb 6, 2024 | ||||||
| Nov 1, 2023 | ||||||
| Aug 1, 2023 | ||||||
| May 9, 2023 | ||||||
| Feb 7, 2023 | ||||||
| Nov 1, 2022 | ||||||
| Aug 9, 2022 | ||||||
| May 10, 2022 | ||||||
| Feb 17, 2022 | ||||||
| Nov 2, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 6, 2021 | ||||||
| Feb 10, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 6, 2020 | ||||||
| May 5, 2020 | ||||||
| Feb 25, 2020 | ||||||
| Oct 30, 2019 | ||||||
| Jul 31, 2019 | ||||||
| May 1, 2019 | ||||||
| Feb 12, 2019 | ||||||
| Nov 1, 2018 | ||||||
| Aug 1, 2018 | ||||||
| May 2, 2018 | ||||||
| Feb 26, 2018 | ||||||
| Nov 1, 2017 | ||||||
| Aug 2, 2017 | ||||||
| May 1, 2017 | ||||||
| Feb 27, 2017 | ||||||
| Nov 3, 2016 | ||||||
| Sep 30, 2016 | ||||||
| Aug 3, 2016 | ||||||
| May 4, 2016 | ||||||
| Nov 10, 2015 | ||||||
| Aug 11, 2015 | ||||||